 Johnathan Goree
Concepts (101)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Pain | 5 | 2023 | 151 | 2.390 |
Why?
| | Racism | 3 | 2022 | 56 | 1.640 |
Why?
| | Spinal Cord Stimulation | 5 | 2023 | 29 | 1.570 |
Why?
| | Nerve Block | 2 | 2018 | 37 | 1.250 |
Why?
| | Dexamethasone | 2 | 2019 | 435 | 1.130 |
Why?
| | Pain Management | 7 | 2022 | 155 | 1.070 |
Why?
| | Analgesics, Opioid | 8 | 2024 | 500 | 0.850 |
Why?
| | Opioid-Related Disorders | 2 | 2022 | 367 | 0.800 |
Why?
| | Analgesics | 2 | 2020 | 107 | 0.790 |
Why?
| | Complex Regional Pain Syndromes | 1 | 2020 | 9 | 0.760 |
Why?
| | Catheter Ablation | 2 | 2020 | 131 | 0.710 |
Why?
| | Hematoma, Epidural, Spinal | 1 | 2019 | 2 | 0.690 |
Why?
| | Hospitals | 2 | 2024 | 188 | 0.690 |
Why?
| | Pain, Postoperative | 2 | 2024 | 160 | 0.670 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2019 | 29 | 0.670 |
Why?
| | Clonidine | 1 | 2018 | 24 | 0.670 |
Why?
| | Physicians | 1 | 2022 | 244 | 0.660 |
Why?
| | Bupivacaine | 1 | 2018 | 28 | 0.660 |
Why?
| | Cervical Vertebrae | 1 | 2019 | 65 | 0.660 |
Why?
| | Anesthetics | 1 | 2018 | 36 | 0.650 |
Why?
| | Diabetic Neuropathies | 3 | 2023 | 55 | 0.610 |
Why?
| | Glucocorticoids | 1 | 2019 | 234 | 0.580 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 540 | 0.510 |
Why?
| | Internship and Residency | 1 | 2020 | 502 | 0.490 |
Why?
| | Pain | 6 | 2024 | 404 | 0.480 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2017 | 281 | 0.460 |
Why?
| | Humans | 20 | 2024 | 54304 | 0.340 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 309 | 0.330 |
Why?
| | United States | 5 | 2022 | 5204 | 0.330 |
Why?
| | Pain Measurement | 2 | 2022 | 248 | 0.230 |
Why?
| | Electric Stimulation Therapy | 1 | 2023 | 26 | 0.220 |
Why?
| | Aged | 4 | 2022 | 10054 | 0.220 |
Why?
| | Self Concept | 1 | 2022 | 71 | 0.210 |
Why?
| | Disabled Persons | 1 | 2023 | 105 | 0.210 |
Why?
| | Insurance Coverage | 1 | 2022 | 108 | 0.200 |
Why?
| | Anxiety Disorders | 1 | 2022 | 138 | 0.200 |
Why?
| | Opiate Substitution Treatment | 1 | 2022 | 80 | 0.190 |
Why?
| | Medicare | 1 | 2022 | 245 | 0.190 |
Why?
| | Ganglia, Spinal | 1 | 2020 | 51 | 0.190 |
Why?
| | Saline Solution, Hypertonic | 1 | 2020 | 18 | 0.180 |
Why?
| | Salvage Therapy | 1 | 2020 | 145 | 0.180 |
Why?
| | Medicaid | 1 | 2022 | 267 | 0.180 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 118 | 0.180 |
Why?
| | Lidocaine | 1 | 2020 | 48 | 0.180 |
Why?
| | Epidural Space | 1 | 2019 | 10 | 0.170 |
Why?
| | Injections, Epidural | 1 | 2019 | 10 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2023 | 5609 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 227 | 0.170 |
Why?
| | Female | 8 | 2022 | 28457 | 0.160 |
Why?
| | Educational Measurement | 1 | 2020 | 232 | 0.160 |
Why?
| | Healthcare Disparities | 1 | 2021 | 270 | 0.160 |
Why?
| | Mastectomy | 1 | 2018 | 143 | 0.150 |
Why?
| | Health Services Accessibility | 1 | 2022 | 427 | 0.150 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 426 | 0.150 |
Why?
| | Clinical Competence | 1 | 2020 | 444 | 0.140 |
Why?
| | Quality of Life | 2 | 2023 | 922 | 0.070 |
Why?
| | Adult | 2 | 2022 | 14189 | 0.070 |
Why?
| | Prospective Studies | 2 | 2023 | 2604 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 1693 | 0.070 |
Why?
| | Arkansas | 2 | 2022 | 2097 | 0.070 |
Why?
| | Caenorhabditis | 1 | 2004 | 1 | 0.070 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2004 | 60 | 0.060 |
Why?
| | Caenorhabditis elegans | 1 | 2004 | 147 | 0.060 |
Why?
| | Back Pain | 1 | 2023 | 44 | 0.060 |
Why?
| | Spinal Cord | 1 | 2023 | 153 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 462 | 0.050 |
Why?
| | Organizational Culture | 1 | 2021 | 46 | 0.050 |
Why?
| | Transcription Factors | 1 | 2004 | 622 | 0.050 |
Why?
| | Faculty | 1 | 2021 | 84 | 0.050 |
Why?
| | Patient Safety | 1 | 2021 | 121 | 0.050 |
Why?
| | Injections | 1 | 2020 | 61 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2024 | 6462 | 0.050 |
Why?
| | Electrodes | 1 | 2020 | 39 | 0.050 |
Why?
| | Buprenorphine | 1 | 2022 | 135 | 0.050 |
Why?
| | Mammary Glands, Animal | 1 | 2020 | 69 | 0.040 |
Why?
| | Ethics, Medical | 1 | 2020 | 41 | 0.040 |
Why?
| | Chickens | 1 | 2020 | 118 | 0.040 |
Why?
| | Program Evaluation | 1 | 2021 | 379 | 0.040 |
Why?
| | Random Allocation | 1 | 2020 | 308 | 0.040 |
Why?
| | Male | 4 | 2022 | 27335 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2020 | 742 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2021 | 2389 | 0.030 |
Why?
| | Animals | 2 | 2020 | 14402 | 0.020 |
Why?
| | Middle Aged | 1 | 2021 | 13076 | 0.020 |
Why?
| | Prophase | 1 | 2004 | 1 | 0.020 |
Why?
| | Sex Determination Processes | 1 | 2004 | 1 | 0.020 |
Why?
| | Oogenesis | 1 | 2004 | 17 | 0.020 |
Why?
| | Disorders of Sex Development | 1 | 2004 | 7 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2004 | 40 | 0.020 |
Why?
| | Fertility | 1 | 2004 | 33 | 0.020 |
Why?
| | Meiosis | 1 | 2004 | 70 | 0.020 |
Why?
| | Species Specificity | 1 | 2004 | 206 | 0.020 |
Why?
| | Genome | 1 | 2004 | 74 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2004 | 244 | 0.020 |
Why?
| | RNA Interference | 1 | 2004 | 195 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2004 | 103 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 289 | 0.020 |
Why?
| | Phylogeny | 1 | 2004 | 269 | 0.010 |
Why?
| | RNA | 1 | 2004 | 202 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2004 | 389 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 820 | 0.010 |
Why?
|
|
Goree's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|